Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Expenses: 2011-2024

Historic Operating Expenses for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $462.2 million.

  • Agios Pharmaceuticals' Operating Expenses rose 16.08% to $129.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 18.31%. This contributed to the annual value of $462.2 million for FY2024, which is 10.50% up from last year.
  • Agios Pharmaceuticals' Operating Expenses amounted to $462.2 million in FY2024, which was up 10.50% from $418.3 million recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Operating Expenses registered a high of $462.2 million during FY2024, and its lowest value of $335.9 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $418.3 million (2023), whereas its average is $427.9 million.
  • Data for Agios Pharmaceuticals' Operating Expenses shows a peak YoY increased of 12.65% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' Operating Expenses stood at $335.9 million in 2020, then rose by 12.65% to $378.4 million in 2021, then rose by 6.57% to $403.3 million in 2022, then grew by 3.73% to $418.3 million in 2023, then rose by 10.50% to $462.2 million in 2024.